Sudarshan Pharma Industries Ltd — Important, 15-05-2026: Company Update

Sudarshan Pharma Industries Limited released an Investor Presentation highlighting its journey as a specialty chemicals and pharmaceutical company. Recent strategic moves include a proposed allotment of 20 million USD in FCCB, 25.50 Cr capex acquisition, and a new Polish subsidiary. The company achieved GMP and ISO 9001:2015 certifications for its Hyderabad manufacturing facility. A subsidiary, Ratna Lifescience, significantly improved profitability. Export turnover reached 21.85 Cr recently, with a target of 100 Cr for the upcoming year. Consolidated quarterly and annual financial results showed growth in revenue, EBITDA, and PAT, signaling strong operational performance and strategic expansion for future value creation.